An editorial notes that for the neurologist treating a patient with new-onset neuropathy, it may ultimately still be difficult to confidently assert that a patient’s neuropathy is attributable to fluoroquinolones because it is a rare event and no clear clinical pattern has been defined that differentiates it from other causes of peripheral neuropathies. It adds that based on the data provided, neuropathy may occur up to 180 days from exposure, which further clouds an association. It suggests that at the present time, clinical judgment informed by history, physical examination, and ancillary testing is essential to help decide whether alternative antibiotic use is recommended.